⌂
Home
◈
Markets
▦
Screener
📈
Tools
◎
Portfolio
Skip to content
DFM General
5,851.39
−0.27%
FTSE ADX
9,783.24
−0.26%
TASI
10,123.62
−0.65%
QE Index
8,632.66
−0.01%
S&P 500
7,690.73
+0.41%
Nasdaq 100
29,529.34
+1.17%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
165,966.09
−0.27%
DFM:EMIRATESNBD
AED 31.50
−0.25%
ADX:IHC
AED 352.00
−0.17%
SAU:2222
SAR 25.80
+0.00%
DSMD:QNBK
QAR 15.66
+2.29%
NAS:NVDA
$217.09
+1.38%
NYSE:TSM
$420.22
+1.84%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 299.47
+0.12%
Gold
$4,140.81
−0.59%
Brent
$109.22
−0.54%
BTC
$81,947.69
−0.08%
ETH
$2,400.39
−0.29%
DFM General
5,851.39
−0.27%
FTSE ADX
9,783.24
−0.26%
TASI
10,123.62
−0.65%
QE Index
8,632.66
−0.01%
S&P 500
7,690.73
+0.41%
Nasdaq 100
29,529.34
+1.17%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
165,966.09
−0.27%
DFM:EMIRATESNBD
AED 31.50
−0.25%
ADX:IHC
AED 352.00
−0.17%
SAU:2222
SAR 25.80
+0.00%
DSMD:QNBK
QAR 15.66
+2.29%
NAS:NVDA
$217.09
+1.38%
NYSE:TSM
$420.22
+1.84%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 299.47
+0.12%
Gold
$4,140.81
−0.59%
Brent
$109.22
−0.54%
BTC
$81,947.69
−0.08%
ETH
$2,400.39
−0.29%
☰
Markets
▼
Stock markets
🇦🇪
UAE
DFM · ADX · DFM General
Closed
🇸🇦
Saudi Arabia
Tadawul · TASI
Closed
🇶🇦
Qatar
QSE · QE General
Closed
🇺🇸
United States
Nasdaq · NYSE · S&P 500
Closed
🇮🇳
India
NSE · BSE · Nifty 50
Closed
🇵🇰
Pakistan
PSX · KSE-100
Closed
Other assets
₿
Crypto
Ranked by volume · 24/7
🥇
Gold, FX & economy
Dubai gold, AED crosses, rates
◫
ETFs
Index, sector and gold funds
Explore
▦
Market map
Every market as a heatmap
📅
Calendar & IPOs
Earnings, dividends, listings, releases
⌁
Options flow · Ownership · Politics
US filings and tapes
Screener
▼
⚲
Stock screener
All six markets, one row per company
★
Ready-made screens
Starting points with a point of view
📁
My saved screens
Saved rules with alerts on new matches
⇄
Compare
Up to five, side by side
Crypto
Tools
▼
📈
Charting
Drawings, indicators, replay
▶
Strategy Maker
Write a rule, test it on history
⇄
Compare
Side by side
🔔
Alerts
Price, earnings, screens, strategies
News
Portfolio
⌕
AED
USD
SAR
QAR
INR
PKR
GBP
EUR
KWD
OMR
BHD
☆
♢
☾
Sign in
Create account
👤
Markets
›
United States
› NAS
› BIIB
B
Biogen Inc
NAS:BIIB
Healthcare
CBOE:SPESG
NASDAQ:NBI
$233.48
+0.36%
At close
At close · Tue 20 Oct · ≈
AED 857.46
· Market cap
$34.47B
· Next earnings
Wed 28 Oct
· Extended
$233.50
+0.01%
☆
Watch
🔔
Alert
⇄
Compare
▶
Test a strategy
✦
AI read
Overview
Chart
Financials
Valuation
Forecasts
Dividends
Ownership
Options
Shorts
News
Profile
Biogen Inc · News · TradingHolo
BIIB news
Headlines tagged to this company
TR
Biogen Inc. (BIIB) To Present 76-Week EMPAVELI Kidney Data at ASN
TradingView · 10 h ago
DP
Biotech Stocks At 52-Week Highs - RTSN Rises With IPO, BIIB, CON, HNGE, HSTM
dpa-AFX · 6 d ago
DO
Biogen Stock Could Keep Gaining. A J.P. Morgan Upgrade Is Just the Beginning. — Barrons.com
Dow Jones Newswires · 7 d ago
ST
Biogen (BIIB) Stock Is Up, What You Need To Know
Stock Story · 7 d ago
DO
Bitcoin Lower, But Maintains Range as Oil Climbs — Market Talk
Dow Jones Newswires · 7 d ago
DO
Biogen Gets JPMorgan Upgrade Ahead of Key Data Readouts — Market Talk
Dow Jones Newswires · 7 d ago
DO
Biogen Price Target Raised to $300.00/Share From $210.00 by JP Morgan
Dow Jones Newswires · 7 d ago
ST
BIIB Stock: JPMorgan Sees ‘Increasingly Compelling Catalyst Path’ For Biogen, Raises Price Target To $300
Stocktwits · 7 d ago
SE
Biogen upgraded at JPMorgan with $300 PT on 2027 pipeline catalysts, shares rise
Seeking Alpha · 8 d ago
DO
Biogen Price Target Raised to $270.00/Share From $240.00 by UBS
Dow Jones Newswires · 10 d ago
DO
Biogen Price Target Cut to $256.00/Share From $260.00 by RBC Capital
Dow Jones Newswires · 11 d ago
RE
Global healthcare companies invest billions to boost US presence
Reuters · 13 d ago
BU
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
BusinessWire · 14 d ago
SE
Biogen phase 2 litifilimab data boosts lupus candidate
Seeking Alpha · 17 d ago
RE
Biogen Says Litifilimab Safety Profile Consistent With No New Safety Signals Identified
Reuters · 17 d ago
RE
Biogen's experimental lupus drug shows benefit against skin symptoms
Reuters · 17 d ago
DO
Biogen Reports Positive Phase 2 Results for Skin Lupus Treatment
Dow Jones Newswires · 17 d ago
SE
Design Therapeutics a new overweight at Wells Fargo on Friedreich ataxia program
Seeking Alpha · 17 d ago
GL
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
GlobeNewswire · 17 d ago
ST
Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)
stockstory · 28 d ago
More news →